Geron (GERN) Stock: Expect Topline MDS Data In Early January
Artur Plawgo/iStock via Getty Images Since my May article on Geron (NASDAQ:GERN) when we saw that topline results from the IMerge phase 3 trial of imetelstat in low risk myelodysplastic syndrome patients was to be […]
